<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403763</url>
  </required_header>
  <id_info>
    <org_study_id>2011-101-013</org_study_id>
    <nct_id>NCT04403763</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia</brief_title>
  <official_title>A First-in-Human, Phase 1/2, Dose-ascending, Multicenter, Masked, Randomized, Vehicle-controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AGN-241622 in Healthy Participants and Participants With Presbyopia (Stage 1 and Stage 2) and Efficacy in Participants With Presbyopia (Stage 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      efficacy of AGN-241622 ophthalmic solution for the first time in human participants
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 26, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 9, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-masked and Single-masked. One cohort is single-masked. All other cohorts are Double-Masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Number of patients experiencing a treatment emergent adverse event after single administration of AGN-241622</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>The number of patients who experience one or more TEAE during the treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2a: Number of patients experiencing a treatment emergent adverse event after repeat administration of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>The number of patients who experience one or more TEAE during the treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Terminal elimination half-life (T1/2) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Terminal elimination rate constant (λz) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Maximum plasma concentrations (Cmax) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Apparent total clearance of AGN-241622 from plasma (CL/F)</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Area under the concentration-time curve from time 0 to time t (AUC0-t) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Plasma Pharmacokinetics: Area under the concentration-time curve from time 0 to infinity (AUC0-inf) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Tears Pharmacokinetics: Area under the concentration-time curve from time 0 to time t (AUC0-t) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Tears Pharmacokinetics: Area under the concentration-time curve from time 0 to infinity (AUC0-inf) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Tears Pharmacokinetics: Maximum plasma concentrations (Cmax) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Tears Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Tears Pharmacokinetics: Terminal elimination rate constant (λz) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Tears Pharmacokinetics: Terminal elimination half-life (T1/2) of AGN-241622</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 administered once unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Pupil diameter measurement</measure>
    <time_frame>Day 1</time_frame>
    <description>To evaluate the target receptor engagement of AGN-241622 as compared with vehicle administered once, unilaterally in healthy participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Area under the concentration-time curve from time 0 to time t (AUC0-t) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Area under the plasma/tear concentration versus time curve from time 0 to the end of the dosing period (AUC0-tau) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Maximum plasma concentrations (Cmax) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Minimum plasma concentrations (Cmin) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Terminal elimination rate constant (λz) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Terminal elimination half-life (T1/2) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Apparent total clearance of AGN-241622 from plasma (CL/F)</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Plasma Pharmacokinetics: Accumulation ratio of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Tears Pharmacokinetics: Area under the concentration-time curve from time 0 to time t (AUC0-t) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Tears Pharmacokinetics: Area under the plasma/tear concentration versus time curve from time 0 to the end of the dosing period (AUC0-tau) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Tears Pharmacokinetics: Maximum plasma concentrations (Cmax) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Tears Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Tears Pharmacokinetics: Terminal elimination rate constant (λz) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2a Tears Pharmacokinetics: Terminal elimination half-life (T1/2) of AGN-241622</measure>
    <time_frame>14 Days</time_frame>
    <description>To evaluate the systemic and local pharmacokinetics of AGN-241622 after repeat bilateral administration in participants with presbyopia</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>AGN-241622 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as single drop in one eye or a single drop in each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as single drop in one eye or a single drop in each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-241622 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as single drop in one eye or a single drop in each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-241622 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as single drop in one eye or a single drop in each eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-190584</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered as single drop in each eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-241622</intervention_name>
    <description>Topical eye drop</description>
    <arm_group_label>AGN-241622 Dose 1</arm_group_label>
    <arm_group_label>AGN-241622 Dose 2</arm_group_label>
    <arm_group_label>AGN-241622 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190584</intervention_name>
    <description>Topical eye drop</description>
    <arm_group_label>AGN-190584</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Topical eye drop</description>
    <arm_group_label>Placebo Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 to 65 at the time of study participation

          -  Be a nonsmoker and nonuser of nicotine-containing products within the previous 1 year

          -  Be able and willing to follow study instructions and complete all required study
             visits in the opinion of the study doctor.

        Exclusion Criteria:

          -  History of alcohol or substance abuse within the 5 years prior to study participation

          -  Enrollment in another investigational drug or device study within 30 days of study
             participation.

          -  Women who are pregnant, nursing, or planning a pregnancy during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Chen</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne Chen, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>Healthy Subject</keyword>
  <keyword>Subjects with Presbyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

